Monitoring Response to Methimazole in Graves' Disease

Initial Monitoring Phase

Patients with Graves' disease treated with methimazole should be monitored with thyroid function tests every 2-4 weeks until euthyroidism is achieved, then less frequently during maintenance therapy, as recommended by the American Academy of Family Physicians 1, 2
Check thyroid function tests (TSH and Free T4) every 2-4 weeks after initiating methimazole therapy until the patient becomes euthyroid, according to the American Academy of Family Physicians 1, 2
In highly symptomatic patients with minimal FT4 elevations, T3 measurements can be helpful for monitoring response, as suggested by the Journal of Clinical Oncology 3

The goal of therapy is to maintain Free T4 or Free T4 Index in the high-normal range using the lowest possible methimazole dosage, as recommended by the American Academy of Family Physicians 1, 2

After achieving euthyroidism, continue monitoring thyroid function tests every 4-6 weeks initially, then every 3 months during maintenance therapy, according to the Journal of Clinical Oncology 3, 4
Monitor for transition to hypothyroidism, which can occur during treatment and requires dose adjustment, as noted by the Journal of Clinical Oncology 3

In pregnant patients, measure Free T4 or Free T4 Index every 2-4 weeks and aim to use the lowest possible dose that maintains Free T4 in the high-normal range, as recommended by the American Academy of Family Physicians 1, 2
For persistent thyrotoxicosis (>6 weeks), consider endocrine consultation for additional workup and possible adjustment of therapy, as suggested by the Journal of Clinical Oncology 3, 5
Physical examination findings of ophthalmopathy or thyroid bruit are diagnostic of Graves' disease and should prompt early endocrine referral, according to the Journal of Clinical Oncology 3, 5
Patients with severe symptoms may require hospitalization and additional medical therapies including beta-blockers, steroids, or surgery, as noted by the Journal of Clinical Oncology 3, 5